Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Bluejay Diagnostics Inc

Healthcare US BJDX

4.89USD
0.15(3.16%)

Last update at 2026-06-12T20:12:00Z

Day Range

4.524.93
LowHigh

52 Week Range

1.6516.68
LowHigh

Fundamentals

  • Previous Close 4.74
  • Market Cap2.04M
  • Volume62755
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.84253M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.05M
  • Diluted EPS TTM-15.25

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.84848M -7.71779M -9.95389M -9.29695M -3.48830M
Minority interest - - - - -
Net income -6.84848M -7.71779M -9.95389M -9.22789M -3.72969M
Selling general administrative 3.91M 3.69M 4.31M 4.76M 1.79M
Selling and marketing expenses - 0.00830M 0.28M 0.45M 0.29M
Gross profit -0.17068M -0.19910M -0.78095M 0.05M -
Reconciled depreciation 0.17M 0.20M 0.79M 0.31M 0.15M
Ebit -6.84764M -6.89477M -9.95389M -9.31778M -3.23016M
Ebitda -6.67696M -6.69567M -9.17293M -9.05964M -3.13551M
Depreciation and amortization 0.17M 0.20M 0.78M 0.26M 0.09M
Non operating income net other - - - - -
Operating income -6.95297M -7.16962M -10.31122M -9.31778M -3.23016M
Other operating expenses 6.95M 7.17M 10.31M 9.57M 3.16M
Interest expense 0.00084M 0.82M 0.00000M -0.02083M 0.37M
Tax provision - - - - -
Interest income 0.10M 0.15M 0.16M - -
Net interest income 0.10M -0.67720M 0.16M 0.00000M -0.36746M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00001M -0.06906M 0.24M
Total revenue 0.00000M 0.00000M 0.00000M 0.25M 0.00007M
Total operating expenses 6.95M 7.17M 10.31M 9.37M 3.16M
Cost of revenue 0.17M 0.20M 0.78M 0.20M -
Total other income expense net 0.10M -0.54818M 0.36M 0.02M -0.25814M
Discontinued operations - - - - -
Net income from continuing ops -6.84848M -7.71779M -10.03740M -9.29695M -3.48830M
Net income applicable to common shares - - - -9.29695M -3.48830M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7.12M 6.66M 4.87M 13.52M 21.02M
Intangible assets - - - 0.00446M 0.00462M
Earning assets - - - - -
Other current assets 0.30M 0.58M 0.71M 1.67M 1.61M
Total liab 1.14M 0.93M 1.97M 1.98M 0.64M
Total stockholder equity 5.98M 5.73M 2.89M 11.54M 20.38M
Deferred long term liab - - - - -
Other current liab 0.80M 0.55M 1.11M 0.84M 0.34M
Common stock 0.00006M 0.00006M 0.00012M 0.00202M 0.00201M
Capital stock 0.00006M 0.00006M 0.00012M 0.00202M 0.00201M
Retained earnings -41.51727M -34.66878M -26.95099M -16.99710M -7.69479M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 0.04M 0.02M
Cash 5.16M 4.30M 2.21M 10.11M 19.05M
Cash and equivalents - - - - -
Total current liabilities 1.12M 0.81M 1.77M 1.64M 0.64M
Current deferred revenue - - - - -
Net debt -5.04466M -4.07970M -1.83841M -9.62237M -19.04778M
Short term debt 0.10M 0.11M 0.17M 0.17M -
Short long term debt - - - - -
Short long term debt total 0.12M 0.22M 0.37M 0.49M -
Other stockholder equity 47.49M 40.40M 29.85M 28.54M 28.07M
Property plant equipment - - - 1.70M 0.34M
Total current assets 5.46M 4.90M 2.96M 11.79M 20.66M
Long term investments - - - - -
Net tangible assets - - - 11.54M 20.38M
Short term investments - - - - -
Net receivables - 0.01M 0.04M - -
Long term debt - - - - -
Inventory - - - - 0.00000M
Accounts payable 0.21M 0.15M 0.49M 0.64M 0.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -21.01887M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00791M 0.04M 0.29M 0.03M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 1.66M 1.76M 1.91M 1.73M 0.36M
Capital lease obligations 0.12M 0.22M 0.35M 0.51M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.30678M -0.85448M -1.19927M -0.02395M
Change to liabilities - - - 0.30M -0.07915M
Total cashflows from investing activities -0.17374M -0.30678M -0.70417M -1.19927M -0.02395M
Net borrowings -0.00403M -0.00481M -0.00481M -0.00080M 4.20M
Total cash from financing activities 7.09M 10.22M 1.11M 0.00808M 22.53M
Change to operating activities - - - 0.28M -1.49092M
Net income -6.84848M -7.71779M -9.95389M -9.29695M -3.48830M
Change in cash 0.86M 2.09M -7.90647M -8.93279M 18.14M
Begin period cash flow 4.30M 2.21M 10.11M 19.05M 0.91M
End period cash flow 5.16M 4.30M 2.21M 10.11M 19.05M
Total cash from operating activities -6.05358M -7.81977M -8.31387M -7.74159M -4.36676M
Issuance of capital stock 8.35M 12.07M 1.59M 0.00000M 18.86M
Depreciation 0.17M 0.20M 0.78M 0.31M 0.15M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -0.01767M
Change to inventory - - - 0.00000M 0.08M
Change to account receivables - - - - 0.00000M
Sale purchase of stock - - -0.05908M - 0.02M
Other cashflows from financing activities 7.09M -1.84429M 0.96M -0.02000M 3.97M
Change to netincome - - - 0.67M 0.46M
Capital expenditures 0.17M 0.31M 0.70M 1.20M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.58M -0.63319M 0.67M 0.58M -1.48531M
Stock based compensation 0.00001M 0.02M 0.19M 0.43M 0.07M
Other non cash items 0.04M 0.31M 0.00309M 0.24M 0.22M
Free cash flow -6.22731M -8.12655M -9.01804M -8.94086M -4.39070M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BJDX
Bluejay Diagnostics Inc		 0.15 3.16% 4.89 - - 54.99 0.34 5.67 -0.096
ABT
Abbott Laboratories		 -1.47 1.64% 88.18 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 6.56 2.15% 312.20 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.13 0.16% 80.20 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.26 0.55% 46.91 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Bluejay Diagnostics Inc

360 Massachusetts Avenue, Acton, MA, United States, 01720

Key Executives

Name Title Year Born
Mr. Indranil Dey Pres, CEO & Director 1964
Dr. Jason Cook Chief Technology Officer 1982
Mr. Kenneth R. Fisher CPA Chief Financial Officer 1980
Mr. Kevin Vance Chief Commercial Officer 1957
Mark W. Feinberg Chief Medical Advisor NA
Dr. Mark W. Feinberg M.D. Chief Medical Advisor NA
Mr. Indranil Dey Principal Financial, Accounting & Executive Officer, President, CEO and Director 1964
Dr. Jason Cook Chief Technology Officer 1983
Mr. Les DeLuca Vice President of Operations NA
Eryn Graham Marketing Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.